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1. Introduction 
The topical treatment of extraocular or intraocular diseases, especially by eye drops, is the 
best accepted by patients. Treatment with eye drops, however, poses the issue of a poor 
drug bioavailability because the precorneal area, i. e., the site of drug action/absorption, is 
rapidly cleared of drugs by protective mechanisms of the eye, such as blinking, basal and 
reflex tearing, and nasolachrymal drainage. This implies the need of frequent instillations, 
and hence, the risk of side effects. Increasing ocular bioavailability remains a stimulating 
challenge for the formulators of topical systems. An approach to the task has been the 
reduction of drainage rate by increasing the viscosity of liquid preparations (Lee & 
Robinson, 1986) or resorting to mucoadhesive polymers (Hui & Robinson, 1985). The ability 
of a polymer to improve the ocular bioavailability of drugs by adhering to the ocular surface 
and binding the drug to it is a more promising property than the polymer viscosifying 
power (Di Colo et al., 2009), so far as fluid solutions are better tolerated than viscous ones 
(Winfield et al., 1990). The ocular retention of drugs administered by eye drops is also 
potentially improved by colloidal drug carriers, such as liposomes, submicron emulsions, 
nanoparticles and nanocapsules. The drugs are incorporated into these submicron particles 
which can be internalized into the corneal and/or conjunctival cells of the ocular epithelium 
(Alonso & Sanchez, 2009; Nagarwal et al., 2009). Prolonging the residence of drugs in the 
precorneal area serves either the extra- or intraocular therapy. In those cases where a well 
tolerated topical treatment is desired to implement an intraocular therapy, the ocular 
formulation can be made to contain an effective, biocompatible, non-irritant polymeric 
corneal permeability enhancer. 
A description of the structures of the eye that come into contact with topical drug delivery 
systems has been  reported recently (Ludwig, 2005). A summary is given in the next section, 
followed by an outline of the routes of intraocular drug penetration. Polysaccharides such as 
chitosan, xyloglucan, arabinogalactan, cellulose derivatives (methylcellulose, 
hydroxyethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose), 
hyaluronic acid, alginic acid, gellan gum, have been studied extensively as excipients for 
ocular formulations. In the present survey of the literature the relevant properties of 
polysaccharides will be presented and discussed, with emphasis on the functions of 
polymers in the ophthalmic formulations where they have been used. Only polysaccharides 
the ocular tolerability of which has been ascertained will be dealt with. 
www.intechopen.com
 
Biomaterials Applications for Nanomedicine 
 
254 
2. Anatomy and physiology of the eye 
2.1 Structure of the ocular globe 
The human eye is schematically shown in Fig.1. The wall of the eyeball consists of an outer 
coat (sclera and cornea), a middle layer (uveal coat) and an inner coat (retina). The eyelids 
spread the tear fluid over the eye. The rate of shear during blinking (about 20,000 s-1) 
influences the rheological properties of instilled ophthalmic formulations and hence, drug 
bioavailability. 
 
 
Fig. 1. Schematic view of the human eye 
The cornea is a clear, avascular tissue composed of five layers: epithelium, Bowman’s layer, 
stroma, Descemet’s membrane and endothelium. The epithelium consists of 5-6 cell layers. 
The corneal epithelium  is little permeable due to the presence of tight junctions connecting 
cells. High extracellular and low intracellular calcium levels are required for the low 
permeability of tight junctions. On the surface of the epithelium flattened cells are found  
microvilli which enhance the stability of the tear film. 
The conjunctiva is a clear membrane, lining the inner surface of the eyelids, adjoining the 
corneal epithelium. The conjunctiva is vascularized and moistened by the tear film. Its 
epithelium is composed of 5-7 cell layers. The cells are connected by tight junctions, 
therefore the conjunctiva is impermeable to molecules larger than 20,000 Da, whereas the 
cornea is permeable up to 5000 Da. 
A volume of about 2-3 μL of mucus is secreted daily whereby foreign particles and bacteria 
are entrapped and swept by blinking to the drainage system for discharge. The turnover of 
the mucous layer (15-20 h) is much slower than that of the tear fluid. 
2.2 Nasolachrymal drainage system 
The tear fluid is spread on the ocular surface by blinking and collected by the canaliculi, the 
lachrymal sac and the nasolachrymal duct which opens into the inferior nasal passage. The 
tear fluid produced by the lachrymal gland is composed of the following: 
1. Basic tearing (0.5-2.2 μL/min), needed to maintain a tear film on the corneal surface, 
corresponding to a turnover rate of 16%/min while awake. 
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2. Reflex tearing, caused by such stimuli as emotional, chemical or mechanical ones, cold 
temperature, light, which can raise lachrymation up to 300 μL/min, thus clearing drugs 
away. 
Undesired drug absorption through nasal mucosa can occur during drainage. 
2.3 Tear film 
The precorneal tear film (thickness 3-10 μm; volume ∼10 μL) is composed of the following 
layers: 
The superficial lipid layer (thickness 100 nm), which spreads over the aqueous layer during 
eye opening. It contains such lipids as triglycerides, phospholipids, sterols, sterol esters, 
fatty acids, and helps tear fluid to maintain its normal osmolality by limiting evaporation. 
The aqueous layer, which  contains inorganic salts, glucose, urea, retinol, ascorbic acid, 
proteins, lipocalins, immunoglobulins, lysozyme, lactoferrin and glycoproteins. The tear 
fluid has an osmolality of 310-350 mOsm/kg and a mean pH of 7.4. Its buffering ability is 
determined by bicarbonate ions, proteins and mucins. The viscosity is ∼3 mPas, with a non-
Newtonian rheological behaviour. The surface tension is ∼44 mN/m. 
The mucus layer, which forms a gel with viscoelastic properties. Mucins improve the 
spreading of the tear film and enhance its stability and cohesion. The mucus gel entraps 
bacteria, cell debris and foreign bodies forming bundles of thick fibers, which are conveyed 
by blinking to the inner canthus and expelled onto the skin. Mucus, which is charged 
negatively, can bind positively charged substances. 
More recent studies have somewhat revised the above “three layers theory”, proposing a 40-
μm thick film essentially made of mucus with an external lipid layer, but without a distinct 
thin aqueous layer. Mucus is made of glycoproteins (mucins), proteins, lipids, electrolytes, 
enzymes, mucopolysaccharides and water. As the polysaccharide side chains of mucins 
usually terminate in sialic acid (pKa 2.6) the mucins are negatively charged in physiological 
conditions. A combination of cross-linking via disulfide bridges and hydrophobic bonds 
and also through entanglements of randomly coiled macromolecules determines the tertiary 
structure of mucin. 
Various factors influence the mucoadhesion of polymeric ocular delivery systems, linked to 
the composition, physicochemical properties and structure of the tear film. The polymer 
must come into intimate contact with the mucus layer. The polymer chains must be mobile 
and flexible enough to interpenetrate into the mucus to a depth sufficient to create a strong 
entangled network with mucin. The polymer and mucin should interact by hydrogen 
bonding, electrostatic and hydrophobic interactions which depend on the ionic strength and 
pH of the applied vehicle. Decreasing the pH enhances the mucoadhesion of polymers 
containing carboxyls because these groups preferentially interact with mucins in the 
unionized form via hydrogen bonding. On the other hand, the repulsion of carboxylate 
anions which form at higher pH values causes extension of polymer chains and decrease in 
density of such chains, which result in enhancement of chain mobility, interdiffusion and 
physical entanglement. Depending on the pKa of the functional groups of the polymer, 
either hydrogen bonding or entanglement prevails. Then, the precorneal residence of 
mucoadhesive polymers varies from a few hours to one day. 
The tear film is not quite stable. In the short interval between blinks it ruptures with 
formation of dry spots on the cornea, which induces blinking and spreading of a new tear 
film. The breakup time of the tear film depends on dispersion forces, interfacial tension and 
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viscous resistance of the mucus layer. These factors should be taken into account when 
developing mucoadhesive pharmaceutical systems. 
3. Routes of intraocular penetration 
Drugs penetrate across the epithelium into the eye via the transcellular (lipophilic drugs) or 
paracellular (hydrophilic drugs) route (Nanjawade et al., 2007). The main mechanism of 
transepithelial either transcellular or paracellular intraocular penetration of topically 
applied drugs is passive diffusion along their concentration gradients. The cornea provides 
the rate-limiting resistance against penetration of hydrophilic drugs, whereas partitioning 
from the epithelium into the hydrophilic stroma is the rate-liming factor for lipophilic drugs 
(Nanjawade et al., 2007). Permeation of ionizable drugs depends on the chemical 
equilibrium between ionized and unionized species in the tear fluid. The unionized species 
usually penetrates more easily than the ionized species. In the latter instance the type of 
charge affects transcorneal penetration. Indeed, the corneal epithelium is negatively 
charged, in physiological conditions (pH 7.4), hence cationic drugs permeate more easily 
than anionic ones (Nanjawade et al., 2007). In addition to the corneal route, topically applied 
drugs may be absorbed via non-corneal routes. Hydrophilic and large molecules, showing 
poor corneal permeability, can penetrate across the bulbar conjunctiva and underlying 
sclera into the uveal tract and vitreous humor (Nanjawade et al., 2007). Tight junctions of the 
superficial conjunctival epithelium are wider than those in the cornea, therefore, the 
conjunctival permeability of hydrophilic drugs is generally significantly higher than their 
corneal permeability (Nanjawade et al., 2007). However, the conjunctiva is vascularized, 
therefore it is generally considered a site for systemic, hence, unproductive absorption. 
4. Polysaccharides in ocular formulations 
The use of natural polysaccharides in ocular formulations is attractive as these products are 
economical, readily available, non-toxic, potentially biodegradable, generally biocompatible 
and capable of chemical modifications. Such modifications have recently led to derivatives 
with improved biopharmaceutical performances, e.g. rhelogical behavior, mucoadhesivity, 
ability to enhance corneal permeability, easy solubilization. 
4.1 Chitosan and its derivatives 
Chitosan (Ch) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) (Fig.2).  
 
 
Fig. 2. Chitosan structure 
www.intechopen.com
 
Polysaccharides as Excipients for Ocular Topical Formulations 
 
257 
Ch is produced commercially by deacetylation of chitin, which is the structural element in 
the exoskeleton of crustaceans (crabs, shrimps, etc.) and cell walls of fungi. The degree of 
deacetylation in commercial Chs is in the range of 60-100 %. The tremendous potential of Ch 
in the pharmaceutical area is illustrated in several review articles (Alonso & Sanchez, 2009; 
Nagarwal et al., 2009; Dodane & Vilivalam, 1998; Felt et al., 1998; Paul & Sharma, 2000; 
Singla & Chawla, 2001, Di Colo et al., 2008). These point out that Ch is biodegradable, has 
low toxicity and good ocular tolerability, exhibits bioadhesion and permeability-enhancing 
properties and also physico-chemical characteristics that make it suitable for the design of 
ocular drug delivery vehicles. The Ch repeating unit bears a primary amino group 
bestowing a reactivity on the polymer that allows its transformation into derivatives of 
interest as biocompatible and bioactive excipients for ophthalmic drug delivery systems (Di 
Colo et al., 2004a; Zambito et al., 2006a; Zambito et al., 2007). Over the last decade efforts 
have been made to put into evidence the ability of Ch to safely promote intraocular drug 
penetration by enhancing corneal permeability, and to synthesize Ch derivatives with 
improved such bioactivity. The significant results of these efforts will be discussed in the 
next subsections. 
4.1.1 Eye drops 
The main role of Ch in ocular solutions was to improve ocular drug bioavailability by 
prolonging drug residence in precorneal area in virtue of polymer mucoadhesivity and effect 
on viscosity (Alonso & Sancez, 2009). More recently Ch solutions have been investigated for 
their ability to improve intraocular drug bioavailability, following topical administration, by 
enhancing corneal permeability. Although the ability of Ch to permeabilize nasal mucosa and 
intestinal epithelium has been known since 1994 (Illum et al., 1994; Artursson et al., 1994) the 
permeabilizing effect of this polymer applied via eye drops on the cornea was demonstrated 
for the first time ten years later (Di Colo et al., 2004b). Unlike the intestinal and nasal epithelia, 
both made of a single layer of cells joined by tight junctions, the cornea is a stratified 
epithelium the cells of which also are joined by tight junctions. Therefore, the ability of Ch to 
enhance the permeability of intestinal and nasal epithelia would not necessarily imply a 
similar effectiveness on the corneal epithelium.  
Instead of using the excised cornea, as in previous studies of the enhancement of corneal 
permeability to drugs, the permeabilizing effect of Ch was investigated in vivo (Di Colo et 
al., 2004b) . To this purpose, ofloxacin was instilled into the eyes of albino rabbits via 
isoviscous eye drops containing Ch hydrochloride (Ch-HCl), or N-carboxymethyl Ch 
(CMCh) (Muzzarelli et al., 1982), or poly(vinyl alcohol) (PVA), and the resulting 
pharmacokinetics in tear fluid and aqueous humor were determined (Di Colo et al., 2004b). 
CMCh, a polyanion at the physiological pH of the tear fluid (Fig.3), was tested to ascertain 
the relevance of the polycationic nature of Ch-HCl and because CMCh was claimed to 
behave as an intestinal absorption enhancer (Thanou et al., 2001).  
 
 
Fig. 3. Structure of N-carboxymethyl chitosan. 
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Only small differences among the rates of drug disappearance from tear fluid were 
measured for the three solutions, reflecting the small differences among the respective 
viscosity values. Such values were high enough to ensure the presence of drug in tear fluid 
at measurable concentrations after about 1.5 h of instillation. Although the time of drug 
residence in the precorneal area was almost the same for the three solutions containing Ch-
HCl, CMCh or PVA, the respective pharmacokinetic data for the aqueous humor were 
neatly distinct. This was taken as a sign of different effects of polymers on the corneal 
permeability. PVA produced an increase of tmax with respect to the reference Exocin
®, which 
was ascribed to the increased viscosity of the PVA solution with respect to the commercial 
eye drops, causing a reduction of tear fluid drainage, and hence, of the precorneal 
elimination rate. This polymer, however, produced no permeabilization of the cornea, 
indeed, there was no significant increase of neither concentration peak (Cmax) nor 
bioavailability (AUC) in the aqueous. On the other hand, Ch-HCl produced Cmax and AUC 
values remarkably higher than the respective values for the reference, at the same tmax. Then 
unlike the case of PVA, with Ch-HCl the increased viscosity of the solution was found to 
cause no prolongation of tmax. These pharmacokinetic data were taken as indicative of an 
increase of the corneal absorption rate constant, due to an enhancement of corneal 
permeability by Ch-HCl. 
More recently the effects of Ch and other non-polymeric permeabilizers on the permeation 
of acyclovir across excised rabbit cornea have been studied (Majumdar et al., 2008). Ch was 
solubilized at the concentration of 0.1 or 0.2% by 2% acetic acid added to Dulbecco’s 
phosphate buffered saline. The apparent corneal permeability (Papp) was determined by 
normalizing the permeant flux to the permeant concentration in the donor. In the presence 
of 0.2 and 0.1% Ch the transcorneal acyclovir permeability was enhanced almost 5.8-fold 
(7.61x10-6 cm/s) and 3.1-fold (4.1x10-6 cm/s), respectively, over that of acyclovir alone 
(1.32x10-6 cm/s).  
The use of unmodified Ch in eye drops as a cornea-permeabilizing agent is not quite 
rational because of problems with its solubility in tear fluid at the physiological pH of 7.4. 
Although Ch-HCl is in the dissolved, and hence, bioactive state just as applied, yet its 
permeability-enhancing effect is presumably temporary. Indeed Ch requires pH ≤ 5 for 
dissolution, hence it is expected to precipitate as the free base some time after instillation, as 
soon as the physiological pH of the tear fluid is restored. For this reason the effect of CMCh, 
a polyanionic Ch derivative soluble at this pH (Fig.3), on transcorneal drug absorption is of 
particular relevance. Although CMCh was found to behave as an intestinal absorption 
enhancer (Thanou et al., 2001) , it failed to significantly enhance corneal permeability, in fact, 
the drug levels produced in the aqueous by CMCh never exceeded the Cmax for the reference 
Exocin® (Di Colo et al., 2004b). Then it appears that the polycationic nature of Ch is essential 
to its permeabilizing effect on the cornea. Interestingly, however, the drug concentration in 
the aqueous vs. time data relative to CMCh pointed to zero-order transcorneal absorption 
kinetics. This observation prompted the hypothesis that CMCh might mediate a pseudo-
steady-state transcorneal transport, via polymer interactions with the drug and polymer 
adhesion to the corneal mucus (Di Colo et al., 2004b). Such a mucoadhesion could prolong 
the drug residence at the absorption site. Despite the different effects of Ch-HCl and CMCh 
on ofloxacin ocular pharmacokinetics, these polymers increased the drug intraocular 
bioavailability with respect to the reference by about the same factor, as shown by the 
relevant AUC values. CMCh, being a polyanion, is potentially able to bind cationic drugs. 
Then it can prolong the precorneal residence of, e.g., aminoglucoside antibiotics at effective 
antimicrobial concentrations, thus allowing reduction of the frequency of instillations. 
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Polycationic derivatives of Ch, soluble in tear fluid at the physiological pH of 7.4, can have 
an increased potential for enhancing the corneal permeability (Di Colo et al., 2004a). A 
similar derivative, i.e., N-trimethylchitosan (TMC), has been obtained by quaternizing the 
primary amino group of Ch with methyl iodide, thus bestowing fixed, pH-independent 
positive charges on the polymer (Fig.4). The complete quaternization is unnecessary to make 
the polymer soluble at neutral or alkaline pH, in fact, a quaternization degree (QD) of 
around 40% is sufficient for this purpose (Snyman et al., 2002; Di Colo et al., 2004a). TMC 
has proved a potent permeation enhancer of hydrophilic molecules and macromolecules 
across the intestinal epithelium in neutral environments (Kotzé et al., 1997; Kotzé et al., 1998; 
Thanou et al., 2000). A study of the enhancing effects of TMC polymers having varying QD 
on the permeation of the hydrophilic mannitol or PEG 4000 across epithelial cell monolayers 
(Caco-2) demonstrated the existence of an optimum QD, beyond which the permeability 
was no further increased (Hamman et al., 2003). 
 
 
Fig. 4. Structure of N- trimethylchitosan. 
It has been shown that TMC is able to enhance the permeability of the rabbit corneal 
epithelium reconstituted in vitro (RRCE) to ofloxacin. A dependence of such a 
permeabilizing ability on the QD of TMC, similar to that found previously with the Caco-2 
intestinal epithelium model (Hamman et al., 2003), has been evidenced (Di Colo et al., 
2004a). The steady-state flux of ofloxacin across the RRCE in the presence of TMCs having 
different QDs was measured and Papp values were calculated by dividing such a flux by the 
drug concentration in the applied solution (0.001% w/v, not cytotoxic to the RRCE cells). 
The Papp enhancement was calculated as the ratio of the Papp value in the presence to that in 
the absence of polymer (enhancement ratio, ER). TMC polymers having low QD (3-4%) were 
barely soluble and ineffective, whereas those having intermediate QD (35-45%) were soluble 
and significantly bioactive (ER 1.5-1.6). TMC polymers having high QD (80-90%) showed no 
further increase of permeability (ER 1.5) (Di Colo et al., 2004a). To explain these findings the 
following hypotheses may be put forward (Di Colo et al., 2004a; Hamman et al., 2003). At 
intermediate QD TMC has favorable chain flexibility and conformation whereas at higher 
QD the TMC electrostatic interactions with the epithelial cell membrane may be hindered by 
steric effects of the attached methyl groups. Another explanation may be the saturation of 
the interaction sites on the membrane. A polycationic polysaccharide, i.e., the fully 
quaternized N-methyl-diethylaminoethyl dextran (MeDEAED) was tested for its ability to 
permeabilize the RRCE. Although MeDEAED has similar charge density and molecular 
weight as the TMC having QD 80%, yet only the latter produced a significant Papp increase 
on the RRCE (Di Colo et al., 2004a). This means that charge density and MW are not the sole 
properties of Chs that concur to determine the ability of these polysaccharides to promote 
transcorneal drug absorption. 
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The TMC polymers with intermediate QD, which had proven effective on the RRCE, were 
also tested in vivo, in the eyes of albino rabbits. The polymers were synthesized from Chs of 
MW 580 kDa (TMCL) and 1460 kDa (TMCH), respectively, in order to investigate the 
relevance of MW to the polymer bioactivity. The pharmacokinetic data for ofloxacin 
obtained in the presence of these derivatives were compared with those obtained with Ch-
HCl (Di Colo et al., 2004a; Di Colo et al., 2004b). For making these comparisons indicative of 
the relative bioactivity of polymers all solutions were made isoviscous using PVA, which 
had been shown to be inert on the cornea (Di Colo et al., 2004b). A significant enhancement 
of transcorneal absorption rate was produced by TMCH, i.e., the Ch derivative with higher 
MW, through an increase of corneal permeability, as could be deduced from increases of 
drug bioavailability and peak concentration in the aqueous (AUC and Cmax, respectively) by 
283 % and 318 %, respectively, over the control. Such an enhancement was also indicated by 
a shortening of the time to peak (tmax). In the presence of TMCH the Cmax exceeded 4 μg/ml, 
which is the MIC90% for the more resistant ocular pathogens (Taravella et al., 1999). On the 
basis of this consideration, TMCH can be regarded as a potential absorption enhancer to be 
formulated into ophthalmic ofloxacin solutions for the topical treatment of endophthalmitis. 
A comparison of the data for TMCH with those for Ch-HCl showed that the permeabilizing 
effect of the partially quaternized derivative is stronger that that of the hydrochloride of 
unmodified Ch. This was indeed predicted in the foregoing discussion on the basis of 
considerations about polymer solubility. Data for TMCL showed that for this derivative 
Cmax was significantly lower and tmax longer than the corresponding values for TMCH, 
which points to a weaker enhancing effect of TMCL. The stronger effect of the derivative 
having the higher MW was ascribed to its stronger adhesion to the corneal mucus (Di Colo 
et al., 2004a). Indeed it was reported that mucoadhesion, along with the opening of tight 
junctions, is a key element of TMC polymers for being effective as absorption enhancers at 
mucosal surfaces (Snyman et al., 2003). 
The absorption-enhancing efficacy of TMC was thought to depend on its charge density 
which, in neutral or alkaline environments, is determined by its quaternization degree 
(Hamman et al., 2003). In the light of this consideration, novel chitosan derivatives with 
pendant quaternary ammonium groups were prepared by reacting Ch with 2-
diethylaminoethyl chloride (DEAE-Cl) under different conditions (Zambito et al., 2006b). 
The general structure of these derivatives, assessed by NMR analysis, is depicted in Fig.5.  
 
 
Fig. 5. Structure of N,O-[N,N-diethylaminomethyl(diethyldimethylene ammonium)nmethyl] 
chitosans. 
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They are assigned the general code, N+-Ch, referring to their nature of quaternary ammonium 
(N+)-chitosan (Ch) conjugates. The degree of substitution by the pendant chain (DS) and the 
mean number of quaternary ammonium groups in the chain (n) depend on the MW of the 
starting Ch and on the molar ratio between reactant (DEAE-Cl) and Ch repeating unit, used in 
the synthesis. A Ch from shrimp shell (MW=590 kDa), with a reagent excess of 4:1 yielded a 
derivative, N+-Ch-4, with values of the parameters, DS and n, higher than those of N+-Ch-2, 
obtained with a reagent excess of 2:1 (DS=132, n= 2.5 vs. DS=40, n=1.6). The transcorneal 
penetration-enhancing properties of N+-Ch-2 and N+-Ch-4 were tested ex vivo on the excised 
rabbit cornea, using the lipophilic dexamethasone and the hydrophilic fluorescein sodium as 
permeabilization probes (Zambito et al., 2007). The results were compared with corresponding 
data obtained with a TMC having a QD of 46%, synthesized from the same Ch as that used to 
prepare the N+-Ch conjugates. Dexamethasone was applied on the cornea as a suspension, 
hence the relevant Papp values were calculated by dividing the steady-state flux by the drug 
aqueous solubility. A significant binding of fluorescein to the Ch derivatives was measured by 
a dynamic dialysis technique, so the concentration of free fluorescein applied to the cornea 
was used to calculate the relevant Papp. 
TMC and the N+-Ch derivatives of whichever DS and n, each at the concentration of 1% 
w/v, enhanced the Papp of the hydrophobic dexamethasone across the excised cornea to 
about the same extent. On the other hand the ER value for  the hydrophilic probe fluorescein 
sodium was the lowest with N+-Ch-2 (the less substituted), intermediate with TMC, and the 
highest with N+-Ch-4 (the more substituted). The apparent difference between the polymer 
effects on the corneal permeability of dexamethasone and fluorescein reflects the difference 
in the corneal structures on which the effects were probably exerted, that is, the membrane 
of the corneal cells, in the case of dexamethasone, and the tight junctions connecting the 
corneal cells, in the case of fluorescein (Zambito et al., 2007).  
N+-Ch-4 has been tested for its ability to promote the intraocular penetration of 
dexamethasone or fluorescein in vivo, in rabbit eyes (Zambito et al., 2007). The intraocular 
availability of dexamethasone was much higher than that of fluorescein in the reference eye 
drops. This reflected a much better partitioning of the lipophilic dexamethasone in the 
corneal cell membrane. In fact, fluorescein transcorneal penetration from the reference eye 
drops was almost insignificant essentially because of a poor partitioning of the permeant in 
the cornea. N+-Ch-4 significantly enhanced intraocular absorption of fluorescein. In fact the 
results of the ex vivo and in vivo experiments agree in indicating a much stronger 
enhancement effect of this polymer on fluorescein than on dexamethasone. Yet the 
enhanced Papp, AUC and Cmax values for fluorescein, which reflect the enhanced availability 
of this highly polar drug model in the aqueous humor, remained lower than the respective 
values for the non-polar dexamethasone. This means that the paracellular route across the 
cornea, which is the more likely for very polar molecules, such as fluorescein sodium, 
remains difficult to penetrate despite the permeabilizing action of the Ch derivatives. On the 
other hand the use of such enhancers as TMC and N+-Ch conjugates may turn profitable for 
improving the effectiveness of existing commercial ophthalmic formulations of such drugs 
as dexamethasone and ofloxacin. 
As in the cases of protonated or quaternized Chs, the activity of which as epithelial 
permeability enhancers is now well documented (see, e.g., Di Colo et al., 2008), an 
electrostatic interaction with negatively charged sites in the mucus, on the cell membranes, 
or in the tight junctions joining epithelial cells is supposed to be at the basis of the 
bioactivity of the N+-Ch conjugates. The more significant representatives of these derivatives 
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are characterized by degrees of substitution of 40-60% (Zambito et al., 2008). The 
comparatively high fraction of free, unsubstituted primary amino groups still available on 
the polymer backbone has been used for covalent attachment of thiol-bearing compounds, 
via formation of 3-mercaptopropionamide moieties. This has led to water-soluble thiolated 
quaternary ammonium-Ch conjugates (N+-Ch-SH) the epithelial permeability-enhancing 
potential of which was tested using the Caco-2 cell monolayer and the excised rat jejunum 
as substrates (Zambito et al., 2009). On the basis of the obtained results the quaternary 
ammonium groups of these derivatives were ascribed the ability to reversibly open the 
epithelial tight junctions and also perturb the plasma membrane of the epithelial cells. On 
their part the thiol groups were believed to keep the polymer adherent to the epithelium by 
reacting with the thiols of the epithelial mucus to form disulphide bonds thus favouring the 
permeability-enhancing action of the positive ions. An N+-Ch conjugate with DS=60% and 
n=1.7 was used to synthesize a multifunctional non-cytotoxic thiomer carrying 4.5% thiol-
bearing 3-mercaptopropionamide besides quaternary ammonium groups (Fig.6).  
 
 
Fig. 6. Strcture of thiolated quaternary ammonium-Ch conjugates 
The potential of this N+-Ch-SH thiomer and the parent N+-Ch as bioactive excipients for 
dexamethasone eye drops was evaluated. The drug permeability across excised rabbit 
cornea was enhanced over the control value by the thiomer and the parent polymer to about 
the same extent (3.8 vs. 4.1 times). The mean precorneal retention time (MRT) and AUC in 
the aqueous of dexamethasone instilled in rabbit eyes via eye drops were enhanced by the 
thiomer (MRT=77.96±3.57 min, AUC=33.19±6.96 µg ml-1 min) more than the parent polymer 
(MRT=65.74±4.91 min, AUC=21.48±3.81 µg ml-1 min) over the control (MRT=5.07±0.25 min, 
AUC=6.25±0.65 µg ml-1 min). The quaternary ammonium ions were responsible for both 
permeabilization of corneal epithelium and polymer adhesion to precorneal mucus, while 
the thiols increased the latter. This synergistic action is the basis of the higher thiomer 
bioactivity in vivo (Zambito & Di Colo, 2010).  
4.1.2 In situ-gelling systems 
It is now known that prolonged-release ocular inserts, though causing some discomfort to 
patients, can remarkably increase the drug ocular bioavailability with respect to the 
traditional eye drops (Saettone & Salminen, 1995; Di Colo et al., 2001a; Di Colo et al., 2001b). 
It was found that ocular inserts based on poly(ethylene oxide) (PEO) immediately after 
application in the lower conjunctival sac of the rabbit eye formed mucoadhesive gels, well 
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tolerated by the animals; then the gels spread over the corneal surface and eroded (Di Colo 
et al., 2001a; Di Colo et al., 2001b). In order to evaluate the potential of Ch as an intraocular 
drug absorption promoter ofloxacin was selected as a drug of practical interest and Ch-HCl 
microspheres medicated with this drug were dispersed into PEO (MW 900 kDa) in the PEO-
Ch-HCl (9:1) wt proportion. Erodible ocular inserts, each containing a dose of 0.3 mg 
ofloxacin, were obtained by compression of the mixture. They were fairly tolerable in the 
precorneal area of rabbits. The ofloxacin concentration profiles in the aqueous, following 
administration of a 0.3 mg dose by the PEO-Ch-HCl (9:1) insert, or a medicated PEO insert 
not containing Ch-HCl, or commercial Exocin eye drops were obtained along with the 
relevant pharmacokinetic data (Cmax, tmax, AUC) (Di Colo et al., 2002). 
As expected, the inserts produced remarkable (one order of magnitude) increases of the 
AUC values, hence of intraocular bioavailability, over the commercial eye drops. The 
medicated Ch-HCl microspheres dispersed in the PEO insert produced no substantial 
bioavailability change with respect to the plain PEO insert. However, with the PEO-Ch-HCl 
(9:1) insert the Cmax value was significantly increased over that produced by the Ch-HCl-free 
PEO insert (7.16±0.77 vs. 4.39±0.58 μg ml-1), while the tmax was reduced (150 vs. 300 min). It 
was reasoned that Ch-HCl, once in contact with the cornea, could exert a gradual enhancing 
effect on the corneal permeability which could explain the above data (Di Colo et al., 2002). 
Microspheres of TMC, medicated with dexamethasone or tobramycin sulfate, were 
dispersed into PEO (MW 900 kDa) inserts with the aim of both maximizing the intraocular 
bioavailability of the drugs and studying the permeabilizing effects of TMC on the cornea 
(Zambito et al., 2006a). Introduction of 10% TMC microspheres into PEO inserts did not 
substantially affect the drug release pattern and rate from vehicle, nor the vehicle residence 
time in the precorneal area of rabbits. This allowed assessing the TMC effect on corneal 
permeability simply by comparing the concentration vs. time profiles in the aqueous 
obtained with the TMC-containing and the TMC-free inserts. The presence of TMC in the 
insert significantly increased Cmax (5.69±0.49 vs. 3.07±0.31 μg ml-1) and AUC (619.3±32.5 vs. 
380.5±32.0 μg ml-1min) for a dose of 0.3 mg of the lipophilic dexamethasone, indicating an 
enhancement effect of TMC on the transcellular penetration pathway. This effect could be 
exerted through an interaction with the glycoproteins of the mucous layer covering the 
cornea and/or with the lipid bilayer of the corneal cell membrane (Zambito et al., 2006a). In 
fact, interactions of protonated chitosan with model phospholipid membranes have been 
reported (Chan et al., 2001; Fang et al., 2001). A comparison of pharmacokinetic data for an 
equal dose of the dexamethasone administered as eye drops (Cmax=0.21±0.02μg ml-1; 
AUC=17.1±0.1 μg ml-1min) with those obtained with the inserts shows a tremendous 
potential of inserts for maximizing intraocular drug availability. This compensates for the 
moderate discomfort in situ gel-forming inserts may cause to patients. On the other hand, 
the tobramycin concentration in the aqueous was below the limit of detection, even with the 
TMC-containing insert. It is known that TMC is able to enhance the paracellular penetration 
of hydrophilic molecules or macromolecules across cell monolayers, such as the intestinal 
epithelium, by opening the tight junctions between cells (Kotzé et al., 1997; Kotzé et al., 1998; 
Thanou et al., 2000). The results obtained with tobramycin (Zambito et al., 2006a) 
demonstrate that the tight junctions of such a stratified epithelium as the cornea are not 
effectively opened by TMC, at least to such an extent as to allow therapeutically effective 
penetration of hydrophilic drugs of the tobramycin molecular size. If the cornea is virtually 
impermeable to tobramycin, although the external cell layer might be affected by TMC the 
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deeper layers could remain impervious to this drug. On the other hand, dexamethasone 
could effectively permeate the cornea, hence the TMC action, although exerted on the 
corneal surface, could significantly enhance the apparent permeability of this drug. 
In the foregoing discussion it was shown that the transcorneal penetration of a paracellular 
marker, such as fluorescein sodium, was significantly promoted by the polycationic Ch 
derivatives TMC and N+-Ch, although the enhanced flux remained comparatively low. 
These results can be reconciled with those currently discussed concerning tobramycin by 
considering that the enhancing effect could be measured in the case of fluorescein, but not in 
that of tobramycin, because the detection limit of the analytical method for the former was 
much lower than for the latter (8x10-3 vs. 0.5 μg/ml). In the light of the discussion so far, the 
remarkable promotion of the transcorneal absorption of ofloxacin by TMC (Di Colo et al., 
2004a) is ascribable to a polymer action on the mucous layer covering the cornea and/or on 
the corneal cell membrane, rather than to an effective opening of the tight junctions in all 
layers of corneal cells. 
To overcome  the bioavailability problems associated with the administration of 
conventional eye drops the use of in situ gel-forming systems that are instilled as drops into 
the eye and undergo a sol-gel transition in the cul-de-sac has been proposed (Gupta et al., 
2007). Different combinations of Ch (MW 150 kDa, 75-85% deacetylated) and poloxamer 
(Pluronic F-127) were evaluated for gelling ability and viscosity. The selected formulation 
(0.25% chitosan, 9.0% Pluronic F-127) had a viscosity that could allow easy instillation into 
the eye as drops and rapid sol-to-gel transition in the precorneal area triggered by a rise in 
pH from 6.0 to 7.4 and in temperature from ambient to 35-37 °C. A 0.25% timolol 
concentration usually prescribed for the therapy of glaucoma was added to the formulation. 
This was a clear, isotonic solution having pH 6.0-6.2. The formulation was converted into a 
stiff gel during autoclaving but recovered its original properties after cooling. Transcorneal 
permeation was studied ex vivo using excised goat corneas. The authors report a larger drug 
amount permeated after 4 h with the in situ gelling system (63.41±2.6%) as compared with 
the plain drug solution (42.11±2.1%) (Gupta et al., 2007) . They ascribe this difference to a 
permeabilizing action of Ch on the cornea, on the basis of the renown of Ch as a 
transmucosal permeation enhancer. It should be considered, however that the comparison 
between gelling system and control is based on the cumulative permeation and not on the 
Papp value. Then factors other than corneal permeability might contribute to the difference. 
Ocular irritation was tested by the chick embryo chorioallantoic membrane test (Gupta et al., 
2007). It was found that the in situ gel formulation is nonirritant to mildly irritant and is well 
tolerated. In vivo precorneal drainage of the formulation was assessed by gamma 
scintigraphy, using albino rabbits for the study. The observation of the acquired gamma 
camera images showed good spreading of the in situ-gelling system over the entire 
precorneal area immediately after administration. The curve of the remaining activity on the 
corneal surface as a function of time showed that the plain drug solution cleared very 
rapidly from the corneal region. The drug passed into the systemic circulation, as significant 
activity was recorded in kidney and bladder 2 h after ocular administration. On the other 
hand the in situ gel formulation cleared slowly and no radioactivity was observed in kidney 
and bladder. This behaviour was ascribed to the known bioadhesivity of Ch and to the 
gelation that was induced by Ch and Pluronic F-127 (Gupta et al., 2007). 
Another in situ gel-forming solution was obtained by coupling poly(N-isopropylacrylamide) 
(PNIPAAm), a well-known thermosensitive polymer having a thermoreversible phase 
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transition temperature close to human body surface (Maeda et al., 2006; Taylor & 
Ceranaowski, 1975; Hsiue et al., 2002; Hsiue et al., 2003), with Ch with the hope that this 
novel polymer (PNIPAAm-Ch) might couple the advantages of Ch and PNIPAAm (Cao et 
al., 2007). The ocular pharmacokinetics of timolol maleate, applied by this thermosensitive 
gel-forming system, were measured by microdialysis, a technique for continuously 
monitoring the drug in the rabbit aqueous (Wei et al., 2006; Macha & Mitra, 2001; 
Rittenhouse et al., 2000). By means of the sampling technique the behaviour of the drug was 
studied after the gel-forming solution and the conventional eye drops, both at the 
concentration of 0.5%, were administered in the cul-de-sac. The peak concentrations of 5.58 
and 11.2 ng/ml were reached in the aqueous 15 and 30 min after instillation of the 
conventional eye drops and the thermosensitive gel-forming solution, respectively. It was 
also noted that the AUC for the latter was two-fold greater than that for the former. These 
data suggested that the gel-forming system improved the intraocular bioavailability and 
effectiveness of timolol maleate, which was embedded in the gel and therefore retained in 
the pre-corneal area for a prolonged period. As a hypothesis from the authors, however not 
substantiated by further data, PNIPAAm-Ch might enhance the corneal permeability and 
absorption of timolol maleate due to its positive charge and adhesive characteristics. The 
MTT assay showed little cytotoxicity of PNIPAAm-Ch at concentrations in the 0.5-400 
μg/ml range (Cao et al., 2007).  
4.1.3 Ch-based colloidal drug carriers 
The potential of colloidal drug carriers, such as liposomes, submicron emulsions, 
nanocapsules and nanoparticles in ocular delivery has been put into evidence by a review 
article in 2009 (Alonso et al., 2009). It has been shown that the action of Ch-based 
nanoparticle systems relies on particle interactivity with the corneal or conjunctival 
epithelium cells. The nanoparticles can be uptaken within the epithelial cells without 
causing any damage to them. In this way these nanosystems, once loaded with drugs, might 
make the conjunctival and corneal epithelia reservoirs for drug delivery to the exterior or 
interior of the eye. The interaction between Ch nanoparticles and the corneal and 
conjunctival epithelial surfaces have been investigated (Lehr et al, 1992). The nanoparticles 
were usually obtained by adding a solution of tripolyphosphate to a Ch solution in acetic 
acid. To study the interaction of Ch nanoparticles with ocular structures by 
spectrofluorimetry and confocal fluorescence microscopy, Ch was converted into a 
fluorescent derivative by the reaction between the fluorescein acid group and the Ch amino 
group. The stability of nanoparticles in the presence of proteins and enzymes was deemed a 
crucial issue. The presence of lysozyme was found not to significantly compromise the 
integrity of Ch nanoparticles since only a slight particle size reduction and no surface charge 
modification were observed (Lehr et al, 1992). Fluorescence microscopy of eyeball and lid 
sections confirmed the in vivo uptake of Ch nanoparticles by conjunctival and corneal 
epithelia. In vivo studies in rabbits showed that the nanoparticles were well tolerated by the 
ocular surface structures, which showed no histologic alterations nor abnormal 
inflammatory cells in cornea, conjunctiva and lids, in full consistency with the lack of 
clinical signs (de Salamanca et al., 2006). 
Another potential colloidal drug carrier has been studied, which combines liposomes and 
Ch nanoparticles (Diebold et al. , 2007). The rehydration at 60 °C of a lyophilized mixture of 
Ch nanoparticles, loaded with FITC-BSA, and liposomes led to the coating of nanoparticles 
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with a phospholipid shell. The resulting nanosystem was characterized for size and zeta 
potential (407.8±9.6 nm and +5.8±1.3 mV to 755.3±30.0 nm and +14.7±0.4 mV, depending on 
composition) while its structure was assumed theoretically on the basis of an interaction 
between the positively charged nanoparticles and the negatively charged lipid vesicles, and 
a reorganization of the membranes to cover the nanoparticle surface. All nanosystems, 
namely, Ch nanoparticles, liposomes, and liposome-Ch nanoparticle complexes showed 
physical stability so far as no significant change in particle size was observed by photon-
correlation spectroscopy after 2 h in simulated lachrymal fluid. The underlying hypothesis 
of the authors was that an appropriate combination of liposomes and Ch nanoparticles 
could increase the ability of the resulting system to interact with biological surfaces and cell 
membranes and potentially deliver drugs to target tissues.  
Studies of Ch-coated colloidal systems loaded with tetanus toxoid, indomethacin or 
diazepam, or Ch-based nanoparticles loaded with cyclosporin have been reviewed (Alonso 
& Sanchez, 2009). It was concluded that a Ch coating could add a clear benefit to the 
potential of colloidal systems as ocular drug carriers, and that Ch nanoparticles might 
represent an interesting vehicle for drugs the target of which is the ocular mucosa.  
The preparation of Ch/Cabopol nanoparticles loaded with pilocarpine, a drug used for the 
treatment of glaucoma, has been reported (Huei-Jen et al., 2006). A solution of Ch in 1% w/v 
acetic acid was dropped into a Carbopol dispersion under stirring by a homogenizer to form 
an opalescent suspension of Ch/Carbopol nanoparticles. The pilocarpine-loaded 
nanoparticles were prepared by dissolving the drug in a measured volume of Ch/Carbopol 
nanoparticle suspension and stirring for 48 h. The drug-loaded nanoparticles were isolated 
by ultracentrifugation and dried by lyophilization. The nanoparticles were assumed to be 
formed by ionic interaction between the polycationic Ch and the polyanionic Carbopol. A 
particle size of 294±30 nm, a zeta potential of +55.78±3.41 mV and a pilocarpine 
encapsulation efficiency of 77±4% were reported (Huei-Jen et al., 2006). After pilocarpine in 
various formulations, i.e., eye drops, liposomes, gel and nanoparticles, had been applied in 
the eyes of rabbits, the resulting miotic responses were compared. The decrease in pupil 
diameter was in the rank order of nanoparticles>liposomes>gel>eyedrops. With 
nanoparticles and liposomes the miosis effect lasted up to 24 h. The AUC for the curve of 
decrease in pupil diameter vs. time was the largest for the nanoparticle formulation, 
indicating that this formulation was the most efficient system of the four tested for the 
topical delivery of pilocarpine (Huei-Jen et al., 2006). 
Lipophilic nanoparticles for the delivery of the macrolide rapamycin for 
immunosuppression in corneal transplantation have recently been described (Xu-Bo et al., 
2008). In brief, the preparation of rapamycin-loaded nanoparticles is described by the 
authors as follows. Poly(lactic acid) (PLA) and rapamycin, dissolved in acetone, are added 
under ultrasonication to an aqueous solution containing a Ch-cholesterol conjugate (Ch-
Chol), after which the solvent is removed by evaporation under stirring. The resulting 
nanoparticle suspension is centrifuged to remove the drug not entrapped within the 
particles, and then lyophilized. It is claimed that the amphiphilic Ch-Chol self-aggregates 
into nanoparticles, with hydrophobic microenvironment inside. When PLA was added to 
the aqueous Ch-Chol under ultrasonication the size of the nanoparticles slightly increased to 
about 300 nm, with a zeta potential of +30.3 mV. The presence of PLA favoured the 
entrapment of the hydrophobic drug into the particles. The drug-loaded Ch-Chol/PLA 
nanoparticles and a rapamycin suspension were radiolabeled and the ocular distribution of 
www.intechopen.com
 
Polysaccharides as Excipients for Ocular Topical Formulations 
 
267 
either system was assessed by scintillation counter and single photon emission computed 
tomography (SPECT) image analysis. The rabbits treated with Ch-Chol/PLA nanoparticles 
showed radioactivity fractions remaining on cornea and conjunctiva significantly higher 
than those treated with the suspension of rapamycin. This behaviour is ascribed to the 
mucoadhesive character of the Ch nanoparticles (Xu-Bo et al., 2008), while disregarding the 
possibility of particle internalization by corneal and/or conjunctival cells. The radioactivity 
levels in the aqueous and iris/ciliary body were close to background level. This is taken as 
an indication that the corneal barrier hindered transport of either the drug or the 
nanoparticles. Nevertheless the prolonged residence of nanoparticles on the ocular surface is 
expected to promote drug absorption by the external ocular tissues. The rapamycin-loaded 
Ch-Chol/PLA were used to treat corneal allografts in comparison with the drug-free 
nanoparticles and the rapamycin suspension eyedrops. All of 10 grafts in the untreated 
control group were rejected within 13 days (median survival time, 10.6±1.26 days). Rabbits 
treated with empty nanoparticles rejected the corneal allografts in a median time of 
10.9±1.45 days and none of these grafts survived beyond 13 days. In the group treated with 
the rapamycin suspension, grafts were rejected between 19 and 27 days with a median 
survival time of 23.7±3.20 days, while in the group treated with the rapamycin-loaded 
nanoparticles the median survival time of grafts was 27.2±1.03 days and 50% grafts were 
still surviving by the end of the observation (4 weeks). These results indicated an improved 
immunosuppressive effect compared with rapamycin eye drops (Xu-Bo et al., 2008). 
A very recent report describes the potential use in ocular drug delivery of liposomes coated 
with low molecular weight (8 kDa) Ch (LCh) (Li et al., 2009). LCh was prepared by 
degradation of Ch with H2O2. Liposomes loaded with diclofenac sodium were coated with 
LCh (LChL). These systems, containing 0.1% diclofenac sodium, were compared with a 0.1% 
aqueous solution of the drug (control) for their effects on drug retention in precorneal area 
of rabbits. The LChL formulations produced significantly higher AUC (area under 
concentration in tear fluid vs. time curve) and longer MRT than either non-coated liposomes 
or the control solution, indicating that the LCh coating was essential to prolong the retention 
of liposome-encapsulated drug. No irritation or toxicity, caused by continual administration 
of LChL in a period of 7 days, resulted from an ocular tolerance study. The effect of LChL on 
drug corneal penetration was studied (Li et al., 2009) using excised rabbit cornea and a 
diffusion apparatus (Camber, 1985). The apparent corneal permeability was determined by 
normalizing the permeant steady-state flux to the permeant concentration in the donor (1.0 
mg/ml). The Papp produced by LChL was significantly higher than that relative to non-
coated liposomes, while the latter was not higher than that produced by the aqueous 
solution. According to the authors (Li et al., 2009) the LCh coating could intensify liposome 
binding to the corneal surface, thus facilitating drug absorption into the cornea. In addition, 
the polycationic LCh could enhance the corneal permeability as in the case of the Ch of 
much higher molecular weight, described earlier (Di Colo et al., 2004b). These results are 
interesting in that they show that a Ch of as low a molecular weight as 8 kDa can act as a 
corneal permeabilizer. However, the effect of this Ch on precorneal retention and corneal 
drug permeability is not reported for the case where drug and Ch are applied in solution, so 
the advantages of using a liposome formulation instead of a solution are not neatly 
highlighted by data. 
4.2 Xyloglucan 
Xyloglucan is a polysaccharide derived from tamarind seeds, therefore it is often coded TSP 
(tamarind seed polysaccharide). It has a backbone of β(1→4)-linked glucose residues. Three 
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out of four glucose units are substituted with α(1→6) xylose residues, which are partially 
substituted by β(1→2)-linked galactose, as shown in Fig.7. Some of the galactose residues 
can be further substituted with α(1→2) fucose. TSP is highly water-soluble. 
 
 
Fig. 7. Structure of the polysaccharide derived from tamarind seeds. 
4.2.1 Eye drops 
TSP has been described as a viscosity enhancer with mucomimetic activity. Therefore it is 
currently used in commercial artificial tears for the treatment of dry eye syndrome (DES) 
(Saettone et al., 1997). Concentrations of such antibiotics as gentamicin and ofloxacin in the 
rabbit aqueous humor depended on whether rabbit eyes were topically treated with 
antibiotics alone or drug formulations viscosified with TSP. In the latter instance 
significantly higher intraocular drug levels were observed. Also, the drugs delivered with 
TSP produced significantly higher intra-corneal levels than those attained with the 
corresponding TSP-free formulations. This suggested that TSP enhances corneal drug 
accumulation by reducing the wash-out of drugs (Ghelardi et al., 2000). 
Eye drops containing 3 mg/ml rufloxacin and 10 mg/ml TSP, along with other excipients 
were topically applied to rabbits for the treatment of experimental Pseudomonas aeruginosa 
and Staphylococcus aureus keratitis. Rufloxacin delivered by the polysaccharide reduced P. 
aeruginosa and S. aureus in the cornea at a higher rate than that obtained with rufloxacin 
alone. These results suggested that TSP is able to prolong the precorneal residence time of 
the antibiotic and enhance drug accumulation in the cornea, thereby increasing the intra-
aqueous antibiotic penetration. (Ghelardi et al., 2004). 
4.2.2 In situ-gelling systems 
When xyloglucan is partially degraded by β-galactosidase the resultant product exhibits 
thermally reversible gelation in dilute aqueous solutions, which does not occur with native 
xyloglucan. Gelation is only possible when the galactose removal exceeds 35%. The sol-gel 
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transition temperature was shown to decrease from 40 to 5 °C when the galactose removal 
ratio increased from 35 to 58% (Nanjawade et al., 2007). Xyloglucan formulations have been 
studied for ocular delivery of pilocarpine, using Poloxamer 407 as a positive thermosensitive 
control. The 1.5 wt.% xyloglucan formulation enhanced the miotic response to a degree 
similar to a 25 wt.% Poloxamer 407 gel (Nanjawade et al., 2007). 
4.3 Arabinogalactan 
Arabinogalactan (AG), a natural polysaccharide contained in Larix Occidentalis (Western 
Larch), has been found to be biocompatible in the eye, mucomimetic and mucoadhesive 
(Burgalassi et al., 2007). It is a non-ionic highly branched polysaccharide of the 3,6-β-D-
galactan type, the side chains of which consist of β-galactose and β arabinose residues 
(Gregory & Kelly, 1999).  
4.3.1 Eye drops 
AG dispersions showed a Newtonian non-viscous behaviour (η=1.6 mPas at 10% w/w 
concentration) along with good mucoadhesive properties, useful for retention on the eye 
surface. In fact, a prolonged time of residence in rabbit eyes was ascertained using 
fluorescein-labeled AG. Five percent w/w AG exerted a good protective effect against the 
appearance of corneal dry spots. It also reduced significantly the healing time of an 
experimental corneal lesion. These findings suggested that AG is potentially effective for 
dry eye protection and in the treatment of corneal wounds (Burgalassi et al., 2007). 
4.4 Cellulose derivatives 
Cellulose is a polysaccharide consisting of a linear chain of several hundred to over ten 
thousand β(1→4) linked D-glucose units. The chemical structures of cellulose derivatives 
used in topical ocular formulations (methyl cellulose, hydroxyethyl cellulose, 
hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose) are shown in Fig.8. 
 
 
Fig. 8. Structure of cellulose and its derivatives. 
4.4.1 Eye drops 
Eye drops containing cellulose derivatives, such as methyl cellulose (MC), 
hydroxypropylmethyl cellulose (HPMC) or sodium carboxymethyl cellulose (NaCMC), 
have largely been used as eye lubricants for the treatment of DES. This is characterized by a 
set of alterations of the eye surface which could relate to tear quality, normal makeup of tear 
film and alterations in blinking or regular closing of eyelids which entail a reduction of the 
stability of the tear film and the alteration of the eye surface. HPMC solutions were patented 
as a semisynthetic substitute for tear-film (Hahnenberger, 1997). When applied, an HPMC 
solution acts to absorb water, thereby expanding the thickness of the tear film and resulting 
in extended time of lubricant presence on the cornea and decreased eye irritation (Koroloff 
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et al., 2004). Aside from its widespread commercial and retail availability in a variety of 
products, HPMC has been used as a 2% solution during surgery to aid in corneal protection 
and during orbital surgery. Treatment with an isotonic 0.5%solution of NaCMC found in the 
market (Cellufresh®, Allergan SA, Madrid) produced a significant decrease in the frequency 
of subjective DES symptoms and improvement of tear film interface stability and corneal 
surface wettability compared to controls (Bruix et al., 2006). 
Hydroxyethyl cellulose (HEC) is used as a viscosity-enhancing agent in ophthalmic 
formulations to prolong corneal contact time and increase intraocular drug levels.  
4.4.2 In situ-gelling systems 
Aqueous solutions of MC or HPMC at concentrations in the 1-10 wt.% range are liquid at low 
temperatures, but form gels upon heating. The transition temperature is between 40 and 50 °C 
for MC and between 75 and 90 °C for HPMC. Sodium chloride lowers the sol-gel transition 
temperature of MC to 32-34 °C, while the transition temperature of HPMC can be lowered to 
about 40 °C by reducing the hydroxypropyl molar substitution (Nanjawade et al., 2007). 
Gelation of MC or HPMC solutions is produced by the hydrophobic interaction between 
methoxy-substituted residues. At low temperatures the macromolecules are hydrated and 
interact by simple entanglement. At higher temperatures the hydration of polymer chains 
tends to decrease, chain-chain associations take place, and the system approaches a network 
structure, corresponding to a sharp rise in viscosity. This sol-gel transition has been 
exploited to design in situ gelling systems having low viscosity at 23 °C and forming soft 
gels at 37 °C (Nanjawade et al., 2007). 
4.5 Hyaluronic acid 
Hyaluronic acid (HA) is a high molecular weight, natural and linear polysaccharide 
composed of β-1,3-N-acetyl glucosamine and β-1,4-glucuronic acid repeating disaccharide 
units (Fig.9). This biocompatible, nonimmunogenic and biodegradable polymer is one of the 
most hygroscopic molecules in nature, in fact, HA can hydrate up to 1000 times its dry 
weight. This property is responsible for enhanced hydration of the corneal surface. 
Moreover, ocular topical application of formulations based on hyaluronic acid reduces the 
elimination rate of tear fluid and stabilizes the tear film. This is useful for the treatment of 
DES (Guillaumie et al., 2010).  
 
 
Fig. 9. Structure of hyaluronic acid. 
4.5.1 Eye drops 
Non-Newtonian and shear thinning properties grant HA solutions a high viscosity at low 
shear rate (when the eye is open) and a low viscosity at high shear rate (during blinking) 
thus allowing an even distribution of the solution, improving lubrication of the ocular 
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surface, retarding drainage, improving bioavailability, and reducing discomfort. Another 
important feature of this high molecular weight, anionic biopolymer is its mucoadhesivity, 
which provides effective coating and long-lasting protection of the cornea as well as 
extended residence times on the ocular surface (Guillaumie et al., 2010). Finally, when 
topically instilled on the eye, hyaluronic acid has been shown to promote physiological 
wound healing by stimulating corneal epithelial migration and proliferation of keratocytes 
and to reduce the healing time of corneal epithelium. Topical ophthalmic solutions should 
exhibit a certain degree of viscosity to prevent immediate drainage from the ocular surface 
and provide there high efficacy and long residence time. However, the solutions should not 
be too viscous to avoid blurred vision and to ease their manufacturing process including 
their sterile filtration (Guillaumie et al., 2010). 
4.6 Alginic acid/sodium alginate 
Alginic acid (AA) is a natural hydrophilic polysaccharide distributed widely in the cell 
walls of brown algae. It contains the monomers β-D-mannuronic acid (M) and α-L-
guluronic acid (G), arranged as homopolymeric blocks of M-M blocks or G-G blocks 
together with blocks of alternating sequence (M-G). The polymer forms 3-dimensional 
ionotropic hydrogel matrices, generally by the preferential interaction of calcium ions 
with the G moieties resulting in the formation of inhomogeneous gels (Grant et al., 1973 
via Cohen et al., 1997). 
4.6.1 In situ-gelling systems 
An aqueous solution of sodium alginate (NaAA) can gel in the eye. Alginates with G 
contents of more than 65% instantaneously formed gels upon addition to simulated tear 
fluid, due to ionotropic gelation by Ca++ ions. In contrast, alginates having low G contents 
formed weak gels at a comparatively low rate (Cohen et al., 1997). Pilocarpine was released 
slowly from alginate gels in vitro over a period of 24 h, and the release occurred mostly via 
diffusion from the gels. In agreement with the in vitro results, intraocular pressure (IOP) 
measurements of rabbit eyes treated with 2% w/v pilocarpine nitrate in solution or in the in 
situ gel-forming formulation containing high G-content NaAA indicated that the latter 
significantly extended the duration of the IOP-reducing effect compared to the former (10 h 
vs. 3 h). On the other hand, the effect of low G-content NaAA on the duration and extent of 
IOP reduction was insignificant (Cohen et al., 1997). 
AA has been evaluated as a potential vehicle in ophthalmic in situ-gelling solutions for 
prolonging the IOP-reducing effect of carteolol. In vitro studies indicated that carteolol is 
released slowly from mucoadhesive AA formulations, suggesting an ionic interaction 
between the basic drug and AA. IOP measurements of rabbit eyes treated with a 1% 
carteolol formulation with or without AA showed that this polymer significantly extended 
the duration of the IOP-reducing effect to 8 h. AA produced an ocular bioavailability 
increase of a carteolol formulation, as indicated by a drug concentration in the target tissue, 
following a once-daily administration, equivalent to a twice-daily administration of the AA-
free carteolol solution (Sechoy et al., 2000).  
4.7 Gellan gum 
Gellan gum (GG), commercial name Gelrite®, is a water-soluble polysaccharide produced by 
the bacterium Pseudomonas elodea. The repeating unit of the polymer is a tetrasaccharide 
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consisting of two residues of D-glucose and one of each L-rhamnose and D-glucuronic acid, 
in the following sequence: [D-Glc(β1→4)D-GlcA(β1→4)D-Glc(β1→4)L-Rha(α1→3)]n. 
4.7.1 In situ-gelling systems 
GG solutions form gels in the presence of mono- or divalent cations, therefore a 0.6% GG 
solution containing 0.34% timolol maleate underwent a sol-gel transition in the rabbit eye 
due to the presence of sodium and calcium ions in tear fluid. In vitro release of timolol from 
GG gelled solutions was retarded and controlled by drug diffusion in the gel. Accordingly,  
in vivo the formation of the gel prolonged the precorneal residence time, and therefore, it 
increased the ocular bioavailability of timolol in the cornea, aqueous humor and iris+ciliary 
body of rabbits (Rozier et al., 1989). A similar in situ-gelling behaviour and in vitro release of 
the antibacterial agent pefloxacin was reported of a 0.6% GG solution. This allowed 
attainment of the minimum inhibitory concentration of antibacterial in the aqueous of 
rabbits, and maintained it for 12 h, while with the conventional eye drops the drug 
concentration in the aqueous after the same time interval dropped to negligible values 
(Sultana et al., 2006). 
4.8 Polysaccharide mixtures  
Mixtures of polysaccharides have been investigated considering that possible interpolimer 
non-covalent interaction might generate excipients for eye drops, having synergistically 
improved properties over those of the separate polymers. Ascertaining the above possibility 
and evaluating the composition of the mixture corresponding to the strongest interaction 
and optimal biopharmaceutical properties have been the fundamental purposes of these 
studies. 
4.8.1 Eye drops 
An interaction between TSP and HA in aqueous solution was ascertained. Various TSP/HA 
mixtures were studied, among which the 3/2 ratio showed the strongest interaction. The 
properties of this mixture as a potential excipient for eye drops were synergistically 
improved over those of the separate polymers. Information about the nature of interpolymer 
interactions and their dependence on TSP/HA ratio was obtained by nuclear magnetic 
resonance (NMR) spectroscopy. The affinity of the TSP/HA (3/2) mixture for mucin, 
assessed by NMR, is higher than that of the single polysaccharides. The mucoadhesivity of 
this mixture, evaluated in vitro by NMR or viscometry, and in vivo by its mean and 
maximum residence time in rabbit precorneal area, is stronger than that of the component 
polysaccharides or the TSP/HA mixtures of different composition. TSP/HA (3/2) is little 
viscous and well tolerated by rabbit eyes, so it shows a considerable potential for the 
treatment of DES. This mixture stabilizes the tear film, hence it has been shown to prolong 
the residence of drugs, such as ketotifen fumarate and diclofenac sodium, in tear fluid. It is 
unable to permeabilize the cornea, therefore mucoadhesivity is responsible for the TSP/HA 
(3/2) synergistic enhancement of either extra- or intra-ocular drug bioavailability (Uccello-
Barretta et al., 2010). 
4.8.2 In situ-gelling systems 
The rheological properties of GG, NaAA and GG/NaAA solutions were evaluated. It was 
found that the optimum concentration of GG solution for in situ gel-forming delivery 
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systems was 0.3% w/w and that of NaAA solution was 1.4% w/w. The mixture of 0.2% GG 
and 0.6% NaAA, when gelled by simulated tear fluid, showed a significant enhancement in 
gel strength in physiological conditions. Such a gelled mixture released in vitro the 
anticancer drug matrine most slowly. When the solution of this mixture was instilled in 
rabbit eyes the in situ gelling significantly prolonged drug residence in the precorneal area 
over the time allowed by the GG or NaAA solution alone (Liu et al., 2010). 
A further in situ gel-forming polysaccharide mixture is composed of Ch and GG. Both 
polysaccharides form gels in the physiological conditions of the eye, gelation of Ch being 
activated by the neutral pH of tear fluid, that of GG by the cations of the electrolytes 
contained in such a fluid. The in situ-gelling system composed of 0.25% w/v Ch and 0.50% 
w/v GG was prepared by mixing solutions of Ch and GG in acetate buffer pH 5.5-6.0 and 
ultrapure water, respectively. The system was medicated with 0.25% w/v timolol maleate. 
In vitro transcorneal permeation studies on the formulation showed a significant increase of 
the drug amount permeated across goat cornea in 4 h compared to plain drug solution and 
the in situ-gelling system based on GG alone. This effect was ascribed to the permeation-
enhancing ability of Ch. In vivo precorneal drainage of the formulation was studied in 
rabbits by gamma scintigraphy. Radio-labelled timolol maleate applied as plain solution 
cleared very rapidly from the corneal region, whereas the drug applied by the Ch/GG in 
situ-gel forming formulation was retained on the corneal surface for a remarkably longer 
time (Gupta et al., 2010). 
4.9 Comparison of polysaccharide mucoadhesivity  
Different polysaccharides, i.e., AG, TSP, HA, HEC, have been compared for their ability to 
resist removal from tear fluid. Their mucoadhesivity was compared in vitro, by the polymer-
induced viscosity increase of a mucin dispersion, and in vivo, by the polymer residence time 
in rabbit tear fluid (Di Colo et al., 2009). 
The optimal polymer to be used as an additive in ophthalmic drops should be 
mucoadhesive without increasing the viscosity of the solution to an excessive extent. A 
solution of TSP 0.7% w/v was shown to possess more of these properties than the other 
polymers at comparison, in fact, it exhibited the highest MRT in the rabbit precorneal area. 
HA and HEC, although mucoadhesive, increased the solution viscosity to an excessive 
degree, and this, in addition to worsening the patient compliance, could induce an 
anomalous reflex tearing with consequent acceleration of precorneal clearance. AG, at the 
concentrations at which TSP, HA and HEC were tested, exhibited no significant 
mucoadhesive properties. This polysaccharide, nevertheless, did not increase the solution 
viscosity, so it showed the potential for being used at much higher concentrations, e.g., 5-
10% w/w, at which its mucoadhesivity is significant (Burgalassi et al., 2007). In virtue of its 
mucoadhesivity, TSP 0.7% w/v is supposed to stabilize the tear film. For this reason the 
residence of two different drugs, i.e., ketotifen fumarate and diclofenac sodium, in the 
precorneal area of rabbit eyes was significantly prolonged by this excipient (Di Colo et al., 
2009). 
5. Conclusion 
The polysaccharides, either natural or semi-synthetic, described in the present survey are 
non-irritant to the eye and show an ample array of possible solutions to formulation issues 
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in ophthalmology. The polysaccharides introduced in eye drops are mucoadhesive and 
mucomimetic at comparatively low viscosities. Hence they have been used as lubricants of 
the eye surface to treat DES. In virtue of their mucoadhesivity they stabilize the tear film and 
prolong the residence of ophthalmic drugs on the eye surface thereby increasing their extra- 
and intra-ocular bioavailability. Ch and some of its polycationic derivatives, when topically 
applied via eye drops, have shown the additional ability to promote intra-ocular drug 
absorption by reversibly permeabilizing the cornea. It is in virtue of this peculiar ability and 
of mucoadhesivity that Ch has been used to prepare nanoparticles for ocular topical 
application, or added to ophthalmic in situ-gelling systems, based on PEO, poloxamer, or 
PNIPAAm, intended to improve the ocular drug bioavailability. When the basic excipients 
of  in situ-gelling systems were polysaccharides, such as AA/NaAA or GG, the basic 
principles of the drug bioavailability increase were the prolonged retention of gel in 
precorneal area and the slow drug release from gel. 
Most of the in vivo studies of ocular formulations employing polysaccharides have used 
rabbits as the animal model. It must be recognized, however, that the precorneal clearance 
determined in rabbits is not representative of that in humans, mainly due to differences in 
blinking frequency. Such differences may be reflected in differences in shear-thinning of tear 
film, mucoadhesion of polymer and ultimately in drainage of drugs. Nevertheless, the 
inaccuracies due to blinking differences can be considered to be similar for the different 
preparations tested, then the rabbit model is deemed robust for those studies where it has 
been used for comparative purposes.  
6. Abbreviation 
AA   alginic acid 
AG   arabinogalactan 
AUC   area under curve 
Ch   chitosan 
Ch-Chol   chitosan-cholesterol conjugate 
Ch-HCl   chitosan hydrochloride 
CMCh   N-carboxymethyl chitosan 
DEAE-Cl  2-diethylaminoethyl chloride 
DES   dry eye syndrome 
DS   degree of substitution 
ER   enhancement ratio 
FITC   fluorescein-isothiocyanate 
G   guluronic acid unit in AA 
GG   gellan gum 
HA   hyaluronic acid 
HEC   hydroxyethyl cellulose 
HPMC   hydroxypropylmethyl cellulose 
IOP   intra ocular pressure 
LCh   low molecular weight chitosan 
LChL   liposomes coated with LCh 
M   mannuronic acid unit in AA 
MC   methyl cellulose 
MeDEAED  N- methyl-diethylaminoethyl dextran 
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MRT   mean precorneal retention time 
n   mean number of quaternary ammonium groups in the pendant 
   chains of N+-Ch 
NaAA   sodium alginate 
NaCMC   sodium carboxymethyl cellulose 
N+-Ch   N,O-[N,N-diethylaminomethyl(diethyldimethylene   
   ammonium)nmethyl] chitosan 
N+-Ch-SH  thiolated quaternary ammonium-chitosan conjugate 
Papp   apparent permeability 
PEO   poly(ethylene oxide) 
PLA   poly(lactic acid) 
PNIPAAm  poly(N-isopropylacrylamide) 
PVA   poly(vinyl alcohol) 
QD   quaternization degree 
RRCE   rabbit reconstituted corneal epithelium 
SPECT   single photon emission computed tomography 
TMC   N-trimethyl chitosan 
TMCL   TMC synthesized from a Ch of MW 580 kDa 
TMCH   TMC synthesized from a Ch of MW 1460 kDa 
TSP   tamarind seed polysaccharide 
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